CMOS Image Sensors Market Size Worth $10.17 Billion By 2020

The global CMOS image sensors market size was valued at USD 7.21 billion in 2013 and is likely to be worth USD 10.17 billion by 2020. Increasing demand for handheld equipment such as tablets and smartphones has initiated the development of smart sensing approaches with remote diagnostic and monitoring capability.

Global market was 1,601.8 million units in 2013 and is anticipated to reach 2,643.4 million units, growing at a CAGR of 7.5% by from 2014 to 2020. The industry has observed tremendous growth over the past few years owing to the growth of its application industries, particularly medical and automotive. In addition, technological innovations leading to the evolution of refined sensing technology are expected to drive growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cmos-image-sensors-market

Dexterity to manufacture smaller pixel devices and provide high resolution with cost effective approach is expected to be one of the primary factors driving growth. Rising demand for computation and communication equipment has led to a growing need to develop upgraded processes for better optical administration. The requirement for on-chip integration and focal plane processing are still on improvement phase.

Consumer electronics was the largest application accounting for over 50% of the total market revenue in 2013. These sensors are widely used in numerous consumer electronic devices including entertainment devices, home appliances, communication products, and information technology. The CMOS image sensors market for consumer electronics is likely to grow at a CAGR of 3.3% from 2014 to 2020.

With an increasing focus on research & development, sensing equipments have become smaller, cheaper, and more power-efficient, which serves as a gratifying opportunity for industry players. This is particularly beneficial to the healthcare industry as these products help in improving diagnostics and provide appropriate treatments that rely on this technology. Medical applications are anticipated to grow at a CAGR of 9.9% from 2014 to 2020.

Multimedia-enabled equipment provides more benefits with more data safety over the internet. The application of sensing devices for indoor navigation, health monitoring, and related niche segments is anticipated to offer prominent growth opportunity for prosperity of this market. These gadgets are predominantly used in the U.S., however, the market is anticipated to witness significant gains in emerging economies such as China, India, and Brazil.

North America CMOS image sensors market exceeded 30% of the total revenue share in 2013. Focus on technological advancement coupled with high adoption rate of new technologies and gadgets have resulted in established of a large market in the region. However, the market has reached its maturity phase and is anticipated to grow at a CAGR of 4.1% from 2014 to 2020.

Asia Pacific is expected to witness significant gains over the forecast period at a CAGR of 6.6% from 2014 to 2020. The market was valued at USD 2.37 billion in 2012. Availability of large number of semiconductor manufacturers in Asia Pacific, especially in Japan, China and Korea, is projected to bolster market growth in this region. Presence of cheap labor and establishment of production facilities by foreign organizations are anticipated to favorably affect industry growth in this region. Growing demand for latest gadgets owing to increase in disposable income of consumers is anticipated boost market growth to reach an estimated value of USD 3.95 billion by 2020.

Key players include OmniVision Technologies, Sony Corporation, Canon Inc., and Samsung Electronics. Sony Corporation and Samsung Electronics are projected to dominate the CMOS image sensors market in the near future. Companies are constantly engaging in research & development to introduce innovative products in the market.

Samsung Electronics Co. Ltd. has announced its new 8-megapixel R-W-B sensing device based on ISOCELL and NFC integrated circuit technology with advanced frequency performance.In March 2015, OmniVision Technologies Inc. launched the OV8865, a CMOS image sensor positioned on OmniBSI-2 pixel planning. It is utilized in high speed photography with low power consumption application. Samsung Electronics Co. Ltd. introduced a 280-megapixel APC-C image sensor, which employs advanced 65-nanometer and illuminated pixel technology to implement energy-efficiency and better picture aspect.

Healthcare IT Market Size Worth $147.3 Billion By 2027

The global healthcare IT market size is expected to reach USD 147.3 billion by 2027, according to a new report by Grand View Research, Inc., expanding at a CAGR of 10.3% from 2020 to 2027. Increasing prevalence of chronic diseases, growing inclination towards automating, and depending on computationally prepared information to facilitate patients’ database and maintaining a single point of access is driving the demand for healthcare IT solutions. This, in turn, is significantly contributing to market growth.

Moreover, initiatives taken by public and private organizations to transform the existing healthcare infrastructure by providing more advanced healthcare IT solutions are anticipated to drive the market during the forecast period. In June 2020, GE Healthcare launched Thoracic Care Suite to detect chest X-Ray abnormalities such as pneumonia and tuberculosis caused by COVID-19 as well as to support clinicians and health systems to ensure quick diagnosis and effective treatment for patients.

In 2019, North America dominated the market owing to increasing demand for quality healthcare, growing focus on patient safety and care, increasing implementation of tele-monitoring, tele-orientation, and tele-consultation services. In addition, rising awareness of EHRs is expected to drive the market in the region. On the other hand, Asia Pacific is anticipated to be the fastest growth during the forecast period owing to the increasing incidence of chronic diseases, growing geriatric population, government initiatives to support the adoption of technology-driven tolls, and the increasing prevalence of COVID-19 in the region. For instance, in June 2020, the government launched the Make in India’s healthcare sector plans to develop healthier societies and support newer models of telemedicine.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/healthcare-it-market

Further key findings from the report suggest:

The growth of the healthcare IT market is owing to rising geriatric population and growing demand for preventive healthcare services
The Electronic Health Records (EHRs) segment dominated the market in 2019, owing to increasing implementation of EHRs in healthcare facilities
North America dominated the market in 2019 owing to improved healthcare infrastructure and the rising prevalence of chronic diseases in the region.

Transdermal Drug Delivery System Market Worth $81.4 Billion By 2024

The global transdermal drug delivery system market is expected to reach USD 81.4 billion by 2024, according to a new report by Grand View Research, Inc. The unprecedented global shift in the adoption of unhealthy lifestyles is presumed to be responsible for the high prevalence of chronic diseases, such as cancer and diabetes, which is expected to drive the clinical urgency to incorporate transdermal drug delivery systems in the future treatments. Moreover, the rising geriatric population base, which is highly susceptible to developing the aforementioned chronic diseases are expected to propel the demand for highly efficacious pharmacological drugs.

The market is driven by technological advancements in transdermal drug delivery devices, which is anticipated to serve the market with future growth opportunities. These advancements include advanced, third-generation, transdermal drug delivery technologies including iontophoresis, ultrasound, and microneedles or mechanical arrays. These technologies serve as effective transdermal drug diffusion alternatives that are capable of improving overall patient health and quality of life. For instance, the advent of matrix-controlled transdermal drug diffusion comprising a drug reservoir and a thermo effector enhances skin permeation and enables controlled drug delivery.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/transdermal-drug-delivery-systems-industry

Further key findings from the study suggest:

The cardiovascular application segment is expected to exhibit growth at a significant CAGR of over 12.0% during the forecast period. This is a consequence of the high clinical urgency to curb hypertension and the need for precise drug delivery at a constant rate, which has led to the development of transdermal drug delivery systems.
The mechanical array in the technology segment is anticipated to witness an exponential CAGR of over 12.5%. The lucrative growth is attributed to the availability of different forms of microneedle transdermal systems, such as solid, hollow, and dissolving microneedles, as per the suitability and needs of the patients.
In 2015, North America dominated the overall Transdermal Drug Delivery System Market at over 50.0%. The consistent number of product launches being undertaken and the continual participation of the prominent players in conducting clinical trials are anticipated to promote the incorporation of transdermal drug delivery systems.
The key players are increasingly involved in initiating collaborative strategies and frequent product launches to capture a larger market share. For instance, in September 2014, Noven Pharmaceuticals, Inc. received FDA approval for Minivelle, estradiol transdermal system to be used for the prevention of postmenopausal osteoporosis. Furthermore, in June 2015, Boehringer Ingelheim GmbH sponsored the clinical trials, which investigated the bioequivalence of transdermal clonidine administration.

Liver Diseases Therapeutics Market Growth By Industry Players Till 2022

The liver diseases therapeutics market had value over USD 7,498.0 million in 2014. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.

Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments’ and big companies’ vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.

The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/liver-diseases-therapeutics-market

Nonetheless, risks and side effects linked with existing medication & stringent FDA and other norms approved by the government along with accessibility of varying treatment measures perform as barriers to the industry. The market was dominated by the antiviral drug sector with a value over USD 2631 million in revenue terms in 2014.

Rising population with liver diseases due to increasing number of alcohol consumers is estimated to boost the market share. Alternatively, the antiviral drug is estimated to observer profitable raise of over 8.8% from 2015 to 2022. This is due to the occurrence of drugs in the pipeline.

The market is estimated to be at over USD 12095.0 million by 2022. This is going to happen due to the increasing geriatric population, rising liver ailments like hepatocellular and hepatitis carcinoma along with high requirement for programs on vaccination in developing nations and high spending on growing healthcare in the developed nations.

North America is dominating the global market due to academic and research institutions performing studies related to medical trials. North America had more than 39% share of the global market in 2014 and is anticipated to carry on leading till 2022. Asia Pacific had share over USD 1615.5 million in 2014 and is estimated at CAGR over 8.5% in the future.

Few of the major industries are Abbott Laboratories, Gilead Sciences, Astellas Pharma Inc., GlaxoSmithKline plc, Bristol-Mayers Squibb, and Merck & Co., Inc.

Pressure Relief Devices Market Size Worth $4.1 Billion By 2025

The global pressure relief devices market size is expected to reach USD 4.1 billion by 2025, according to a new study by Grand View Research Inc. The rapidly growing number of elderly population worldwide and rising awareness about pressure ulcers through campaigns along with the increasing base of obese population are expected to drive the industry growth.

The incidence of pressure ulcer development has been rising since the past few years in hospital settings. According to a 2013 study by the Centers for Medicare and Medicaid Services (CMS), healthcare expenditure on hospital-acquired illnesses, including bedsores has increased at a rate of 7% from 2000 to 2013.

Geriatric population is prone to developing bed sores due to impaired mobility. Similarly, obese patients are at higher risk of ulcer development as they are required to stay in hospitals for prolonged periods. The limited mobility amongst these target populations will drive growth in this industry.

Creating awareness about pressure ulcer development is crucial since they are avoidable with proper precautions. Various campaigns such as ‘Stop the Pressure’ have been arranged by the governments to spread the awareness about pressure relief amongst patients and care providers. More than 2.5 million people in the U.S. and 0.7 million people in UK are affected by pressure ulcers every year.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/pressure-relief-device-market

Further Key Findings From the Study Suggest:

Low-tech devices have been identified as the largest type of segment in terms of revenue share, due to easier accessibility and cost-effectiveness of the devices
The focus on technically advanced innovative solutions is considered as the contributing factor to growth of low tech mattresses, especially gel-based mattresses and foam-based mattresses
High-tech devices have been projected as the fastest growing segment over the forecast period followed by low-tech mattresses, due to improved technical features
Amongst the types of low-tech mattresses, foam-based mattresses held the majority of market share in 2015 in terms of revenue owing to the high comfort and low technological complexity, and affordability
On the other hand, gel-based mattresses are expected to be the fastest growing low-tech devices over the forecast period
Dynamic air therapy beds were identified as the largest high-tech segment, while kinetic beds are projected to be the fastest growing segment, owing to the high efficiency and technical advancements
Key players in pressure relief devices market include ArjoHuntleigh; Hill-Rom Holdings, Inc.; Stryker; PARAMOUNT BED CO., LTD.; and Invacare Corporation

Anxiety Disorders & Depression Treatment Market Worth $18.3 Billion By 2025

The global anxiety disorders and depression treatment market is expected to reach a value of USD 18.3 billion by 2025. The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/anxiety-disorders-and-depression-treatment-market

Further key findings from the study suggest:

Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane
Patent expiration of branded medicines and the introduction of generic biosimilars, which are cost-effective, are responsible for the shrinking market of antidepressants
On the other hand, the introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, is predicted to fuel the demand for therapeutics in the coming years
Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
Cognitive-behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

HIV Diagnostics Market Is Expected To Reach USD 4.48 Billion In 2022

Global HIV Diagnostics Market is expected to reach USD 4.48 billion by 2022, growing at an estimated CAGR of 9.5% from 2015 to 2022, according to a new study by Grand View Research, Inc. Key factors accounting for the growth of this market include the growing need in for the development of more sensitive HIV diagnostic point of care tests which can be easily implemented at the location of patient care in resource limited settings. Technological development of tests which is expected to introduce a number of novel rapid, point-of-care tests throughout the forecast period is a primary factor expected to fuel the growth of the HIV diagnostics market. Furthermore, government programs and campaigns initiated against HIV, global healthcare efforts to reduce disease incidence, and the presence of high unmet demand in the Middle Eastern and Eastern regions of the market are some key factors expected to serve as lucrative future growth opportunities.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/hiv-diagnostics-market

Further key findings from the study suggest:

Antibody HIV diagnostic tests accounted for the largest share of the market in 2014. This large share can be accounted for by the high market usage and penetration rates of these tests which include, ELISA, home access dried blood spot, western blot testing IFA and RIPA. These tests are highly sensitive and accurate and thus are most commonly used for screening and confirmation of HIV-1 & HIV-2.
Viral Load testing and CD4 testing also accounted for a considerable share of the market in 2014. There is a prevalent in the market for the development of these tests which will make them more sensitive, rapid in nature and portable to the point of care to enhance their market usability and accessibility in resource limited HIV affected regions.
It is expected that during the forecast period a number of novel point of care HIV diagnostic products will be commercialized which are currently under clinical development and in product pipelines of key market players. This increase in the range of products s expected to fuel the growth of this market over the forecast period.
North America was observed to account for the largest share of the market in 2014, which can be attributed to the presence of a strong healthcare R&D scenario in which the presence of government funding and ongoing corporate efforts to enhance product portfolio are anticipated to accelerate the timelines for new product development. Furthermore, the presence of favorable reimbursements policies for HIV and other infectious diseases is also a factor accounting for this region’s large share.
Asia Pacific is expected to grow at a relatively faster rate over the forecast period owing to, the presence of high levels of unmet market demand for HIV screening and testing. Moreover, collaborations among market participants from the western regions is another significant expected to boost the growth of Asia Pacific HIV diagnostics market during the forecast period.
Key players of the market include Janssen Diagnostics, Daktari Diagnostics, Cepheid, Hologic and Chembio Diagnostic Systmes Inc.

Smoking Cessation & Nicotine De-Addiction Market Worth $21.8 Billion By 2024

The global smoking cessation and nicotine de-addiction market is expected to reach over USD 21.8 billion by 2024 according to a new report by Grand View Research, Inc.

The base of population addicted to smoking is rapidly increasing across the globe. This population subset majorly includes teenagers and the working population. Smoking-related mortality is very high. The increasing desire to quit smoking and the numerous health complications associated with smoking serve as strong incentives for companies to introduce novel smoking cessation products, such as Revolymer, which has introduced the next generation nicotine gums to help smokers quit smoking. The launch of these improved and innovative nicotine replacement therapy products is to serve as a high impact rendering driver for the growth of the smoking cessation and nicotine de-addiction market.

The growing incidence of target diseases such as chronic obstructive pulmonary disease (COPD), asthma, cardiac diseases, and lung cancer, and the increasing awareness pertaining to the hazardous side-effects of smoking are the factors expected to promote market expansion. Educational institutions remain active in organizing various campaigns and programs to spread information about the harmful effects and consequences of smoking so as to increase young population awareness.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/smoking-cessation-and-nicotine-de-addiction-products-market

Further key findings from the study suggest:

Nicotine Replacement Therapy (NRT) dominated the smoking cessation and de-nicotine addiction product market in 2015. Majorly used NRT products include nicotine chewing gums and the transdermal patches. Increased availability and the introduction of the ingestible nicotine products with different flavors are the factors responsible for its large market share.
The e-cigarette segment is anticipated to grow at a CAGR of19.0% over the forecast period. The major factors responsible for the growth of the E-cigarette market include the introduction of second and third generation e-cigarettes, the availability of various flavored products, the presence of numerous vendors operating and selling e-cigarettes under different brand names.
North America held a large market share of over 35.0% in 2015 owing to the high awareness levels of nicotine de-addiction products with around 90% of the U.S. population were identified as aware of e-cigarettes in 2015
Asia Pacific is the fastest growing market. The registration of nicotine de-addiction products and e-cigarettes as well as the strengthening of the company distribution channels in countries, such as China, India, and Australia are expected to support the growth over the forecast period
Some key players of this market are Pfizer, Inc., Cipla Ltd., Novartis International AG, GlaxoSmithKline plc, Takeda pharmaceutical Company Ltd., McNeil AB, Revolymer plc, Imperial Tobacco Ltd., and VMR products, LLC
The market players are making slow but steady progress in the e-cigarette market by focusing on the development, commercialization, and distribution of the FDA approved nicotine products. For instance, in 2014, Victory Electronic Cigarettes Corporation acquired Ten Motives Ltd. with an aim to expand their distribution channels and attain wider market coverage.

Biosimilars Market Size Worth $61.47 Billion By 2025

The global biosimilars market size is expected to reach a value of USD 61.47 billion by 2025, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 34.2% over the forecast period. Major biological drugs are approaching the patent cliff. This is the most significant driving factor for the market. For instance, Roche’s MabThera/Rituxan (rituximab), a monoclonal antibody biologics was approved by the U.S. Food and Drug Administration (FDA) in November 1997 and its U.S. patent expired in September 2016. Several companies such as Amgen, Boehringer Ingelheim, and Pfizer are focusing on the development of biosimilar drugs of rituximab.

Furthermore, the lower cost of biosimilars compared to patented biologics and positive outcomes in clinical trials are expected to boost market growth. For instance, in July 2016; Allergan plc and Amgen stated results from a Phase 3 clinical study of ABP 980 compared with trastuzumab, a recombinant DNA-derived humanized monoclonal antibody. This drug was approved for early and metastatic breast cancer and metastatic gastric cancer in many regions. Currently, there is a boom in the pharmaceutical industry for the development of biosimilar drugs, which is a cost-saving alternative to biologic drugs. Amgen Inc.; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Biocon; Samsung Bioepis; and Mylan N.V are some of the companies focusing on the development and production of biosimilars.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/biosimilars-market

Further key findings from the report suggest:

In 2016, the recombinant non-glycosylated protein was the largest revenue-grossing segment in the biosimilars market owing to the prevalence of growth hormone deficiency and diabetes and other chronic diseases
Recombinant glycosylated protein segment is expected to grow at a significant rate during the forecast period owing to demand erythropoietin and monoclonal antibodies for the treatment of cancer and anemia
Oncology accounted for the largest share in the application segment in 2016 due to increasing adoption of low-cost biosimilar drugs for cancer treatment
Europe was the leading regional segment in terms of revenue share in 2016 owing to favorable regulatory policies
North America is expected to witness the highest CAGR during the forecast period owing to the high prevalence of chronic diseases and a rising number of drug approvals
Some of the major players are Amgen Inc.; F. Hoffmann-La Roche Ltd.; Sandoz International GmbH; Dr. Reddy’s Laboratories Ltd.; Teva Pharmaceutical Industries Ltd.; Pfizer Inc.; Samsung Bioepis; Biocon; and Mylan N.V.

Nuclear Medicine Market Size Worth $12.6 Billion By 2027

The global nuclear medicine market size is expected to reach USD 12.6 billion by 2027, expanding at a CAGR of 9.5%, according to a new report by Grand View Research, Inc. Research and development of advanced technologies by the key players for diagnosis and treatment of diseases is expected to drive the radiopharmaceuticals market.

For instance, in May 2019, GE Healthcare with Indi Molecular, Inc., collaborated to develop Protein Catalyzed Capture (PCC) technology and immune cell-targeted PET tracer candidates. This diagnostic tool will help in better understanding of patient’s immune cell and in early treatment response.

Rising prevalence of cancer and cardiovascular diseases is one of the major factors responsible for market growth. Moreover, high prevalence of cancer in emerging Asian countries is creating huge demand for radiopharmaceuticals in diagnosing the disease. For instance, according to the GLOBOCAN, in 2018, approximately 48.4% of cancer cases were registered in Asia.

In addition, presence of standard guidelines prepared by regulatory authorities for radiopharmaceuticals is expected to accelerate market growth. For instance, in August 2019, FDA published a guideline for non-clinical studies and product labelling that are not covered by FDA and ICH guidelines for radiopharmaceuticals used in the treatment of cancer.

Manufacturers are focusing on development of innovative technologies to produce medical isotopes that can fulfill the increasing demand for nuclear medicines. For instance, in October 2018, with the support of ASML, The Institute For Radioelements (IRE) developed and built an electron beamline to manufacture medical isotope molybdenum 99 (Mo-99). Due to this innovative technology, the process of production is waste-free and non-fission.

In addition, research centers and hospitals are launching novel nuclear medicine techniques to treat various diseases at an affordable cost as compared to the existing treatments. For instance, in August 2017, the Kovai Medical Centre and Hospital (KMCH) had launched Rhenium 188 Lipiodol to treat liver cancer and other diseases such as metastatic bone pain, rheumatoid arthritis, and hemophilic bleeding joints at low cost with lesser hospitalization.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/nuclear-medicines-market

Further key findings from the study suggest:

In 2019, the SPECT segment had dominated the market owing to integration of SPECT with X-ray/CT that has gained more acceptance and proved to be useful in many clinical situations due to its high accuracy
PET diagnostic nuclear medicine is expected to witness the fastest growth over the forecast period owing to the increasing adoption of high resolution PET scanners
In case of the therapeutic segment, brachytherapy is anticipated to be the fastest growing segment due to the higher radiation protection as compared to other treatment options
The oncology application segment dominated the nuclear medicine market in 2019 owing to the presence of pipeline drugs and high prevalence of cancer
The market in Asia Pacific is projected to witness the fastest growth during the forecast period owing to the high unmet needs and development of radiopharmaceuticals for diagnosis and treatment of various diseases
Key players in the market include companies such as Eckert and Ziegler Group Nordion, Inc.; Bracco Imaging S.p.A.; and GE Healthcare as well as government organizations such as Department of Atomic Energy and Australian Nuclear Science and Technology Organization (ANSTO).